Gilead Sciences' TROP2-targeting drug Trodelvy is already used as a third-line treatment for PD-L1-positive triple-negative breast cancer (TNBC), but could be heading for use in previously untreated ...
Johnson & Johnson has added another piece to the data behind its effort to move Tecvayli into earlier-line therapy for multiple myeloma, including the first relapse setting. In the MajesTEC-9 trial, ...
Defense Secretary Pete Hegseth urged Iran’s leaders to “choose wisely” and said a U.S. blockade of Iranian ports would ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results